{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038045","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.053132+00:00","generated_at":"2026-06-09T14:36:07.118301+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"TenX Keane Acquisition signs definitive merger with Citius Oncology; $675M equity value","bullets":["Deal values Citius Oncology at $675M; Citius Pharma receives 67.5M shares at $10/share.","Citius Pharma to retain ~90% majority ownership in publicly listed New Citius Oncology post-close.","Transaction expected to close first half 2024, subject to shareholder and regulatory approvals.","TenX to domesticate from Cayman Islands to Delaware and rename to Citius Oncology, Inc.","Sponsor 10XYZ Holdings agrees to support deal and waive redemption rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038045","json":"https://secwatch.observer/filing/0001493152-23-038045.json","markdown":"https://secwatch.observer/filing/0001493152-23-038045.md","text":"https://secwatch.observer/filing/0001493152-23-038045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000149315223038045/0001493152-23-038045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000149315223038045/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T14:36:07.118301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2eb5cb7319dab0c6579c841fc17197f8d96743bf","claim":"CITIUS ONCOLOGY, INC. entered into Agreement and Plan of Merger and Reorganization with TenX Keane Acquisition, TenX Merger Sub, Inc., Citius Pharmaceuticals, Inc. (effective 2023-10-23).","evidence_excerpt":"On October 23, 2023, TenX Keane Acquisition, a Cayman Islands exempted company (“ TenX ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement” ), by and among TenX, TenX Merger Sub, Inc., a Delaware corporation and wholly owned Subsidiary of TenX (“ Merger Sub ”), Citius Pharmaceuticals, Inc., a Nevada corporation (“ Citius Pharma ”), and Citius Oncology, Inc., a Delaware corporation and wholly owned subsidiary of Citius Pharma (“ Citius Oncology ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851484/000149315223038045/0001493152-23-038045-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"TenX Keane Acquisition, TenX Merger Sub, Inc., Citius Pharmaceuticals, Inc."},{"label":"Effective","value":"2023-10-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}